Mesoblast could be a positive surprise for Teva shareholders, in our view.
Congestive heart failure (CHF) is an unmet medical need. Teva is developing Mesoblast’s proprietary Mesenchymal Precursor Cells, or MPCs (Revascor), for cardiovascular and neurological diseases. Trials in CHF are the most advanced. The phase II data showed no mortality and no CHF-related hospitalization during the follow-up period (30 months). We expect the phase III trial to enroll ~1,700 patients globally with primary endpoints (mortality and hospitalizations). Alone, this is a multi-billion dollar market—but we believe Mesoblast’s potential goes much deeper than CHF. Cheers Vin
Mesoblast could be a positive surprise for Teva shareholders, in...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $4.300M | 3.903M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 25260 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 50560 | 19 |
View Market Depth
| Last trade - 15.00pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |